

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70, and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated January 28, 2016,
1. Indiana University Health Bloomington Hospital	3. License number 13-10408-02 is amended in its entirety to read as follows:
2. P.O. Box 1149 Bloomington, IN 47402	4. Expiration date November 30, 2020
	5. Docket No. 030-01644 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed sources (Best Medical International, Inc. Model 2300 Series, 3M Health Physics Services Model 6711, and Bard Brachytherapy Inc. Model STM 1251)	D. 1.5 curies
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed sources (Theragenics Corp. TheraSeed Model 200)	E. 500 millicuries
F. Cesium-131 permitted by 10 CFR 35.400	F. Sealed sources (IsoRay Model CS-1)	F. 500 millicuries
G. Any byproduct material permitted by 10 CFR 31.11	G. Prepackaged Kits	G. 2 millicuries

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. through F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - G. In vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 72

CONDITIONS

10. A. Licensed material shall be used only at the licensee's facilities located at 605-625 West Second Street, Bloomington, Indiana.
- B. **Licensed material listed in Subitems 6.A. through 6.C. may also be used at the licensee's facilities located at 500 Landmark Avenue, Bloomington, Indiana.**
- C. Licensed material listed in Subitem 6.C., limited to strontium-89, phosphorus-32, and samarium-153, may be received and used at the licensee's facilities located at 2620 Cota Drive, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Patrick J. Byrne, DABR, CHP, DABSNM.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

David Y. Lee, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries and to the parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV), 35.400, and 31.11.

Sean M. Flynn, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Douglas D. Geiger, M.D.

10 CFR 35.100, 35.200, and 31.11.

Bruce N. Monson, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Mark A. Bisesi, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

Chris W. McGary, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

John Alexander, M.D.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-10408-02

Docket or Reference Number
030-01644

Amendment No. 72

Authorized Users

Jonathan A. Staser, M.D.

Jennifer Peterson Goldspiel, M.D.

Per Amundson, M.D.

George K. Wolfer, Jr., M.D.

Neal David Abdullah, M.D.

Todd A. Winkler, M.D.

Nicholas P. Miller, M.D.

Material and Use

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, and 31.11.

10 CFR 35.100, 35.200, **and** 35.300 (limited to the oral administration of sodium iodide I-131).

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 11, 2010 (ML101750066)
- B. Letter dated March 13, 2012 (ML12088A162, with attached facility diagram)
- C. Letter dated April 5, 2013 (ML13101A144)
- D. **Letter dated January 28, 2016 (ML16077A339)**
- E. **Letter dated March 20, 2016 (ML16084A947)**
- F. **Letter dated June 15, 2016 (ML16166A392)**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 15 2016

By Sara A. Forster
Sara A. Forster, M.S.
Materials Licensing Branch
Region III